Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126763 · ClinicalTrials.gov registry record · Phase 3
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain
A Phase 3 study, sponsored by ZARS Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
NCT00126763 is a Phase 3 study that was terminated before completion, run by ZARS Pharma. The registered enrollment target is 105 participants.
The verdict
NCT00126763, a Phase 3 study, was terminated before completion, sponsored by ZARS Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of non-malignant chronic pain.
Interventions
- DRUG Fentanyl Transdermal Matrix Patch ZR-02-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126763
The ClinicalTrials.gov registry entry for NCT00126763 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fentanyl Transdermal Matrix Patch ZR-02-01 is the first listed.
NCT00126763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00126763 about?
NCT00126763 is a clinical study titled "Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain". The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of non-malignant chronic pain.
What is the current status of trial NCT00126763?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2005-07. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00126763?
The interventions under investigation include: Fentanyl Transdermal Matrix Patch ZR-02-01 (DRUG).
Who is sponsoring clinical trial NCT00126763?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.